 |
|
|
|
CALVENZA™ EHV Reference Page
Description
Calvenza™ EHV is Equine Rhinopneumonitis Vaccine Killed Virus Vaccine.
Features
Unique EHV-1 equine respiratory origin isolate.
Stimulates antibody to EHV-1 & EVH-4.
Proven efficacious against EHV-1 & EHV-4 in challenge studies.
Novel adjuvant.
Safe, all killed vaccine.
Includes innovative pliable nasal applicator.
Benefits
Aids in reduction of respiratory disease caused by EHV-1 & EHV-4.
Flexible dose administration.
No reversion to virulence concern.
Minimal vaccine site reactions.
Three dose regimen conforms to AAEP recommendations.
Advantages
Calvenza EHV is proven safe. Calvenza EHV is proven effective by challenge.
Dosage & Administration
Using aseptic technique inoculate horses IM with a 2 mL dose. Administer a second 2 mL dose IM in 3-4 weeks using a different injection site. Administer a third 2 mL dose in 3-4 weeks either IM or IN. Revaccinate annually and prior to anticipated exposure, either IM or IN.
Precautions
Store at a temperature between 35∞ - 45∞ F (2∞ - 7∞ C). Protect from freezing. Shake well before using. Do not vaccinate within 21 days of slaughter.
Antidote: Epinephrine.
Uses
For the vaccination of healthy, susceptible horses 6 months of age or older, including pregnant mares, as an aid in the reduction of respiratory disease due to equine herpesvirus type 1 (EHV-1) and type 4 (EHV-4).
Warning
This product has been tested under laboratory conditions and shown to meet all Federal standards for safety and efficacy in normal, healthy, immunocompetent animals. This level of performance may be affected by conditions such as stress, weather, nutrition, disease, parasitism, other treatments, individual idiosyncrasies or impaired immunological competency. These factors should be considered by the user when evaluating product performance or freedom from reactions.
Product Information
|
Name
|
Code
|
Size
|
|
Calvenza EHV
|
132-215
|
2 mL 1 dose
|
|
Calvenza EHV
|
132-225
|
20 mL 10 doses
|
|
-
|
-
|
-
|
|
-
|
-
|
-
|
|
-
|
-
|
-
|
Highlights
- Unique EHV-1 antigen & novel adjuvant.
- Proven efficacious against EHV-1 & EHV-4 by challenge studies.
- Flexible routes of administration.
- Proven safe with minimal vaccine site reaction.
- Safe for use in pregnant mares.
Contact Information
Boehringer Ingelheim Vetmedica, Inc.
2621 North Belt Highway
St. Joseph, MO 64506
Information: 800-821-7467
Sales: 800-325-9167
Fax: 816-236-2717
email: techservices-ca@bi-vetmedica.com
internet: http://www.bi-vetmedica.com
General Product Information Documents
Technical Bulletins
Audio & Video
Marketing Documents
Product Photos and Product Art
|
|
|
|
|
